Mantle Cell Lymphoma Trial

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab, and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 Years Old with Untreated Mantle Cell Lymphoma


Mantle cell lymphoma is an aggressive form of lymphoma, and the optimal upfront treatment is still unknown. This phase II trial, led by Nina D. Wagner-Johnston, MD (Johns Hopkins University), will compare three chemotherapy regimens consisting of bendamustine, rituximab, high-dose cytarabine, and acalabrutinib and evaluate how well each one works in treating newly-diagnosed patients.

Physician and Research Staff Educational Material

This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.

Information and Assistance from the National Cancer Institute

    • Locations and other information
    • Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail. ID: NCT04115631

Return to Home Page | Review Other Active Trials